Digital Biomarkers for Adverse Drug Reaction Prediction: Emerging Applications in Pharmacovigilance

Sankpal Srushti[1], Keskar Rutuja[2], Jadhav Sakshi[3], Jogdand Asmita[4], Avdhute Prachi[5], Pandhare Akshata[6], Anjikhane Vaibhavi[7], Dange Sanghamitra[8]
[1,2,3,4,5,6,7,8]*Dr. Babasaheb Ambedkar Marathwada University*

***Abstract*—Adverse drug reactions (ADRs) remain a major cause of patient morbidity, mortality, prolonged hospitalization, and increased healthcare expenditure worldwide. Conventional pharmacovigilance systems primarily rely on spontaneous reporting mechanisms, which often suffer from underreporting, delayed signal detection, and incomplete clinical information. Recent advances in digital health technologies have introduced digital biomarkers as novel tools for continuous monitoring of physiological, behavioral, and environmental parameters. Digital biomarkers are objective, quantifiable measures collected through wearable devices, smartphones, electronic health records (EHRs), and connected medical devices. These biomarkers offer real-time insights into patient health status and enable early identification of drug-related adverse events. The integration of digital biomarkers with artificial intelligence (AI), machine learning (ML), and big-data analytics has significantly enhanced the capability to predict ADRs before clinical manifestation. Furthermore, digital biomarker-driven pharmacovigilance supports personalized medicine by identifying individual risk factors and facilitating proactive interventions. This review discusses the concept of digital biomarkers, their sources, mechanisms of ADR prediction, applications in pharmacovigilance, emerging technologies, challenges, regulatory considerations, and future perspectives. The review highlights how wearable sensors, mobile health platforms, and predictive analytics are transforming traditional pharmacovigilance into a proactive and patient-centered surveillance system.**

***Index Terms*—Digital biomarkers, Adverse drug reactions, Pharmacovigilance, Artificial intelligence, Machine learning, Wearable devices, electronic health records, Signal detection.**

I. INTRODUCTION

Adverse drug reactions (ADRs) represent a significant public health concern and contribute substantially to healthcare burden across the globe. ADRs can lead to increased hospitalization, treatment discontinuation, reduced therapeutic effectiveness, and, in severe cases, mortality. Despite advancements in drug development and regulatory oversight, many ADRs remain undetected during premarketing clinical trials due to limited sample sizes, short study durations, and restricted patient populations [1].

Pharmacovigilance encompasses the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Traditional pharmacovigilance systems primarily depend on spontaneous reporting databases, healthcare professional reports, and post-marketing surveillance programs. Although these systems have played a vital role in ensuring medication safety, they frequently encounter challenges such as underreporting, reporting bias, delayed recognition of safety signals, and incomplete patient information [2].

The rapid growth of digital health technologies has created opportunities for more efficient and proactive pharmacovigilance practices. Wearable devices, smartphones, remote monitoring systems, and electronic health records continuously generate large volumes of patient-related data. These technologies facilitate the collection of objective physiological and behavioral measurements that can serve as digital biomarkers for disease monitoring and drug safety assessment [3].

Digital biomarkers are defined as objective, quantifiable physiological and behavioral data collected and measured through digital devices such as

wearable sensors, smartphones, implantable devices, and connected health technologies. Unlike conventional biomarkers obtained during periodic clinical visits, digital biomarkers enable continuous monitoring and real-time assessment of patient status. Parameters such as heart rate variability, physical activity, sleep quality, respiratory patterns, skin temperature, electrocardiographic signals, and medication adherence can be continuously captured and analyzed to identify subtle changes associated with adverse drug effects [3,4,5].

The emergence of machine learning and artificial intelligence has further expanded the utility of digital biomarkers in pharmacovigilance. Advanced analytical algorithms can process multidimensional datasets from wearable devices and EHRs to identify patterns indicative of impending ADRs. Recent studies have demonstrated the growing use of machine learning models for predicting adverse drug events using healthcare datasets, thereby enabling earlier intervention and improved patient safety [4,5].

Digital biomarkers provide several advantages over traditional monitoring approaches. Continuous data collection allows earlier detection of physiological abnormalities, while integration with predictive analytics supports individualized risk assessment. Additionally, digital biomarker-based systems may facilitate real-time pharmacovigilance by automatically identifying abnormal physiological responses associated with medication exposure [6].

Recent literature indicates increasing interest in utilizing biomarkers and digital health technologies within pharmacovigilance frameworks. Biomarkers have been investigated for signal detection, toxicity assessment, risk stratification, and prediction of ADR severity. The integration of digital biomarker data with pharmacovigilance databases offers opportunities for improved safety monitoring and precision medicine approaches [2].

This review aims to comprehensively examine the role of digital biomarkers in ADR prediction and pharmacovigilance. Particular emphasis is placed on wearable technologies, electronic health records, machine learning methodologies, real-world evidence generation, regulatory challenges, and future directions for implementing digital biomarker-driven pharmacovigilance systems.

II. DIGITAL BIOMARKERS: TYPES, SOURCES, AND CHARACTERISTICS

2.1 Concept of Digital Biomarkers

Digital biomarkers are objective, quantifiable physiological and behavioral measurements collected through digital technologies and used to explain, influence, or predict health-related outcomes [7]. Unlike traditional biomarkers that are obtained during clinical visits through laboratory investigations or imaging procedures, digital biomarkers are generated continuously through connected devices operating in real-world settings. These measurements provide a longitudinal representation of patient health and can capture subtle physiological alterations that may precede clinical manifestations of adverse drug reactions (ADRs).

The increasing adoption of wearable sensors, smartphones, mobile health applications, and connected medical devices has accelerated the generation of digital health data. Such technologies facilitate continuous monitoring of patients receiving pharmacotherapy and enable early identification of abnormal physiological responses potentially associated with medication use [8].

Digital biomarkers are particularly valuable in pharmacovigilance because ADRs often develop gradually and may remain unnoticed until significant clinical deterioration occurs. Continuous monitoring allows detection of early physiological deviations, creating opportunities for prompt intervention and prevention of severe adverse outcomes [9].

2.2 Major Sources of Digital Biomarkers

2.2.1 Wearable Devices

Wearable devices represent one of the most important sources of digital biomarkers. Smartwatches, fitness trackers, wearable electrocardiogram (ECG) monitors, biosensors, and smart patches continuously record physiological parameters such as heart rate, heart rate variability, blood oxygen saturation, physical activity levels, sleep duration and quality, respiratory rate, and body temperature. These measurements provide valuable information regarding physiological changes that may occur following medication exposure and can support the early identification of adverse drug reactions [10].

2.2.2 Smartphones and Mobile Health Applications
Smartphones possess multiple embedded sensors capable of collecting behavioral and physiological data. Accelerometers, gyroscopes, microphones, touch-screen interactions, and geolocation systems enable assessment of mobility, cognitive function, social engagement, and daily activities [11].
Changes in digital behavior patterns may serve as early indicators of medication-related adverse effects. Reduced mobility, altered communication patterns, or abnormal smartphone usage may reflect fatigue, depression, dizziness, or cognitive impairment induced by medications [12].

2.2.3 Electronic Health Records (EHRs)
Electronic health records constitute a rich source of digital biomarkers. EHR systems contain comprehensive patient information, including demographic characteristics, medication histories, laboratory test results, clinical diagnoses, hospitalization records, and comorbid conditions. The integration of these data elements enables researchers and healthcare professionals to evaluate medication safety more effectively and develop predictive models for adverse drug reactions [13].

2.2.4 Remote Monitoring Systems
Examples of remote monitoring technologies include continuous glucose monitoring systems, remote ECG monitoring devices, blood pressure monitoring systems, smart inhalers, and connected insulin delivery systems. These technologies continuously generate patient-specific physiological data that can be utilized to assess medication safety, monitor treatment responses, and facilitate early detection of adverse drug reactions in real-world settings [14].

2.2.5 Social Media and Digital Phenotyping Platforms
Digital phenotyping refers to the collection of behavioral and physiological data through personal digital devices. Social media activity, online behavior, language usage, and digital interactions can provide indirect biomarkers associated with drug response and adverse effects [15].
Natural language processing (NLP) algorithms can identify patient-reported symptoms and adverse events from social media platforms, thereby complementing traditional pharmacovigilance systems [16].

III. MECHANISMS OF ADVERSE DRUG REACTION PREDICTION USING DIGITAL BIOMARKERS

3.1 Early Physiological Signal Detection
Many ADRs are preceded by subtle physiological changes before clinical symptoms become apparent. Digital biomarkers facilitate continuous monitoring and enable identification of these early warning signals [17].
For example, QT interval prolongation may precede serious cardiac arrhythmias, reduced oxygen saturation may indicate pulmonary toxicity, changes in gait and mobility may suggest neurological adverse effects, and altered sleep patterns may signal psychiatric complications. Detection of these physiological changes before the onset of clinically apparent symptoms can facilitate earlier intervention and reduce the severity of adverse drug reactions [17]. Detection of these changes enables earlier intervention and may reduce the severity of ADRs.

3.2 Pattern Recognition Through Machine Learning
Commonly utilized machine learning algorithms include Random Forest, Support Vector Machine, Gradient Boosting, Artificial Neural Networks, and Deep Learning models. These analytical approaches can process large volumes of multidimensional healthcare data and identify complex relationships between physiological parameters, medication exposure, and adverse outcomes. Their ability to recognize subtle patterns improves the accuracy of ADR prediction and supports individualized patient care [18,19].

3.3 Risk Stratification
Risk stratification models commonly incorporate variables such as age, sex, genetic predisposition, comorbid conditions, polypharmacy, physiological sensor data, and previous adverse drug reaction history. By integrating these diverse factors, predictive models can estimate an individual's likelihood of developing medication-related adverse events and support personalized treatment decisions [20].

3.4 Real-Time Pharmacovigilance
Traditional pharmacovigilance systems rely largely on retrospective reporting. In contrast, digital biomarker-based systems enable proactive pharmacovigilance by

continuously monitoring patient health status and automatically generating alerts when abnormal patterns emerge [21].

Real-time monitoring may improve:

- Signal detection speed
- ADR reporting accuracy
- Clinical decision-making
- Medication safety surveillance

The integration of cloud computing and Internet of Medical Things (IoMT) technologies further enhances the scalability of such systems.

Table 1. Major Sources of Digital Biomarkers in Pharmacovigilance

Source	Examples	Potential ADR Applications
Wearable Devices	Smartwatches, ECG patches	Cardiotoxicity monitoring
Smartphones	Activity trackers, sensors	Neurological and behavioral ADR detection
EHRs	Laboratory data, prescriptions	Risk prediction models
Remote Monitoring Systems	Glucose monitors, BP monitors	Chronic disease medication surveillance
Social Media Platforms	Patient-reported symptoms	Signal detection and pharmacovigilance

Table 2. Physiological Digital Biomarkers Relevant to ADR Prediction

Biomarker	Measurement Method	Potential ADR Detected
Heart Rate	Wearable sensors	Cardiotoxicity
Heart Rate Variability	Smartwatches	Autonomic dysfunction
Oxygen Saturation	Pulse oximetry	Respiratory toxicity
Sleep Patterns	Wearable devices	Neuropsychiatric ADRs
Activity Levels	Accelerometers	Fatigue and weakness
Body Temperature	Biosensors	Drug-induced fever

IV. ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN ADR PREDICTION

4.1 Role of Artificial Intelligence in Pharmacovigilance

The growing volume of healthcare data generated from wearable devices, electronic health records (EHRs), mobile health applications, and remote monitoring systems has created unprecedented opportunities for the application of artificial intelligence (AI) in pharmacovigilance. Traditional pharmacovigilance approaches are often limited by manual data processing and delayed adverse event reporting. AI-based systems can process large-scale datasets rapidly and identify complex associations between drug exposure and adverse outcomes that may not be apparent through conventional analytical methods [22].

Artificial intelligence facilitates automated signal detection, adverse event classification, risk prediction, and decision support. Machine learning algorithms continuously improve their predictive performance through exposure to new datasets, thereby enhancing the accuracy of ADR detection and prediction [23].

4.2 Machine Learning Approaches Used in ADR Prediction

Several machine learning methodologies have been employed for adverse drug reaction prediction.

Supervised Learning

Supervised learning algorithms are trained using labeled datasets containing known ADR outcomes. These models learn relationships between patient characteristics, medication exposure, and adverse events to predict future occurrences [24]. Commonly used supervised learning methods include Random Forest, Logistic Regression, Support Vector Machines, Gradient Boosting Machines, and Extreme Gradient Boosting (XGBoost). These algorithms are capable of handling large healthcare datasets and have demonstrated substantial effectiveness in identifying patients at risk of adverse drug reactions. Their ability to process multiple clinical variables simultaneously makes them valuable tools in pharmacovigilance and medication safety research [24, 25].

Unsupervised Learning

Unsupervised learning methods identify hidden structures and patterns within datasets without

predefined outcome labels. These approaches are particularly useful for discovering previously unrecognized adverse drug event associations and identifying patient subgroups that may have an elevated risk of developing ADRs. Techniques such as K-means clustering, hierarchical clustering, principal component analysis, and association rule mining enable researchers to explore complex healthcare datasets and uncover meaningful relationships that may not be apparent through traditional statistical analyses.[25]

Deep Learning

Deep learning models utilize multiple neural network layers to extract complex features from high-dimensional datasets. Such approaches are particularly effective when analyzing continuous digital biomarker streams generated by wearable devices and remote monitoring systems. Deep learning has been successfully applied to electrocardiographic signal interpretation, sleep pattern assessment, physical activity monitoring, and continuous physiological surveillance. These models can detect subtle changes in physiological parameters that may precede the onset of adverse drug reactions, thereby improving early detection and intervention strategies.[26]

4.3 Explainable Artificial Intelligence (XAI)

Despite their predictive capabilities, many AI models function as "black boxes," making interpretation difficult. Explainable Artificial Intelligence (XAI) aims to improve transparency by identifying variables contributing to model predictions [27].

In pharmacovigilance, explainability is essential because healthcare professionals must understand the rationale behind safety alerts before making clinical decisions. XAI techniques improve trust, regulatory acceptance, and clinical implementation of AI-driven pharmacovigilance systems. [26,27]

4.4 Integration of Digital Biomarkers and AI

The combination of digital biomarkers with artificial intelligence creates a highly effective framework for proactive drug safety monitoring. Continuous physiological data collected from wearable devices can be analyzed in real time using machine learning algorithms to identify early indicators of adverse events. For example, AI systems can detect drug-induced arrhythmias through continuous ECG monitoring, identify respiratory depression using wearable oxygen sensors, recognize neuropsychiatric adverse effects through behavioral and activity monitoring, and predict metabolic complications using continuous glucose monitoring systems. These integrated approaches facilitate timely clinical intervention and support personalized medication management strategies.[28]

V. APPLICATIONS OF DIGITAL BIOMARKERS IN PHARMACOVIGILANCE

5.1 Cardiotoxicity Monitoring

Cardiovascular adverse effects represent a significant concern for many therapeutic agents, including anticancer drugs, antiarrhythmics, and psychotropic medications. Wearable ECG devices and smartwatches can continuously monitor cardiac function and generate digital biomarkers indicative of cardiotoxicity [29].

Relevant biomarkers include:

- Heart rate variability
- QT interval changes
- Cardiac rhythm abnormalities
- Resting heart rate

Early identification of cardiac abnormalities can facilitate prompt treatment modification and reduce the risk of severe complications.

5.2 Neuropsychiatric Adverse Event Detection

Digital biomarkers are increasingly utilized to identify neuropsychiatric adverse effects associated with medications. Smartphones and wearable devices can capture behavioral patterns reflecting cognitive and emotional changes. Alterations in sleep behavior, reductions in physical activity, changes in social interactions, variations in speech characteristics, and declines in cognitive performance can serve as indicators of medication-induced psychiatric or neurological complications. Continuous monitoring of these parameters provides valuable insights into patient well-being and may support the early detection of depression, anxiety, psychosis, or cognitive impairment associated with pharmacotherapy.[30]

5.3 Monitoring Respiratory Toxicity

Respiratory depression is a serious adverse effect associated with opioid analgesics, sedatives, and

certain neurological medications. Wearable pulse oximeters and respiratory monitoring devices enable continuous assessment of respiratory status [31].
Important biomarkers include:

- Oxygen saturation
- Respiratory rate
- Breathing pattern variability
- Nocturnal respiratory disturbances

Continuous monitoring allows earlier detection of respiratory compromise and may prevent fatal outcomes.

5.4 Detection of Metabolic Adverse Effects

Many medications influence glucose metabolism, body weight, and endocrine function. Digital biomarkers derived from continuous glucose monitoring systems and wearable sensors can facilitate early recognition of metabolic disturbances. These technologies have been applied to monitor antipsychotic-induced metabolic syndrome, detect steroid-associated hyperglycemia, assess the safety and effectiveness of antidiabetic therapies, and evaluate treatment responses in obesity management. Continuous metabolic monitoring may improve therapeutic outcomes and reduce the risk of serious complications. [32].

5.5 Oncology Pharmacovigilance

Cancer therapies frequently produce serious adverse reactions requiring close monitoring. Digital biomarkers can support oncology pharmacovigilance by enabling continuous surveillance of treatment-related toxicity [33].
Potential applications include:

- Fatigue monitoring through activity tracking.
- Cardiotoxicity surveillance during chemotherapy.
- Detection of treatment-induced arrhythmias.
- Monitoring physical function deterioration.

5.6 Post-Marketing Drug Safety Surveillance

Digital biomarkers enhance post-marketing surveillance by providing real-world evidence regarding medication safety after regulatory approval. Continuous patient monitoring through digital health technologies improves the accuracy and completeness of adverse event reporting while facilitating earlier detection of emerging safety signals. These systems reduce delays associated with conventional pharmacovigilance approaches and enable monitoring across broader and more diverse patient populations. Consequently, digital biomarker-based surveillance has the potential to strengthen regulatory decision-making and improve public health outcomes.[34]

VI. CHALLENGES AND LIMITATIONS

6.1 Data Quality and Reliability

The reliability of digital biomarkers depends heavily on the accuracy of underlying devices. Sensor malfunctions, user errors, missing data, and device variability may compromise data quality and affect prediction performance [35].
Standardized validation procedures are therefore necessary to ensure clinical utility.

6.2 Privacy and Data Security

Digital biomarker systems generate large volumes of sensitive personal health information, making privacy and data security critical considerations. Effective implementation requires robust data encryption methods, secure cloud-storage infrastructures, compliance with applicable regulatory requirements, and transparent informed-consent procedures. Addressing these concerns is essential for maintaining patient trust and ensuring the ethical use of digital health technologies within pharmacovigilance systems.[36]

6.3 Lack of Standardization

Currently, no universally accepted standards exist for the development, validation, and implementation of digital biomarkers. Differences in device specifications, data collection methodologies, and analytical approaches create challenges for comparison across studies [37].
International harmonization efforts are required to establish robust regulatory frameworks.

6.4 Algorithmic Bias

Machine learning models may inherit biases present within training datasets, potentially leading to unequal prediction performance across different patient populations. Underrepresentation of certain demographic groups can reduce the accuracy and fairness of ADR prediction models, thereby contributing to healthcare disparities. To minimize algorithmic bias, researchers should utilize diverse and

representative datasets, maintain transparency during model development, conduct rigorous external validation studies, and continuously monitor model performance after implementation.[38]

6.5 Regulatory Challenges

Regulatory agencies continue to develop frameworks governing digital health technologies and AI-based medical systems. Demonstrating safety, effectiveness, reliability, and reproducibility remain essential before widespread implementation [39].

Collaboration among researchers, clinicians, technology developers, and regulatory authorities is necessary to establish clear approval pathways.

Table 3. Applications of Digital Biomarkers in ADR Prediction

Clinical Area	Digital Biomarker	Potential ADR Detected
Cardiology	ECG, HRV	Arrhythmias, QT prolongation
Psychiatry	Sleep and activity patterns	Depression, anxiety
Respiratory Medicine	Oxygen saturation	Respiratory depression
Endocrinology	Continuous glucose monitoring	Hyperglycemia
Oncology	Activity tracking	Chemotherapy toxicity

Figure 1. Conceptual Framework of Digital Biomarker-Based Pharmacovigilance



VII. FUTURE PERSPECTIVES

The future of pharmacovigilance is expected to be increasingly driven by digital health technologies, real-time monitoring systems, and artificial intelligence (AI)-enabled analytics. As healthcare transitions from episodic care toward continuous patient monitoring, digital biomarkers will play a central role in detecting adverse drug reactions (ADRs) before significant clinical manifestations occur.

7.1 Integration with Precision Medicine

Precision medicine aims to tailor therapeutic interventions according to an individual's genetic profile, physiological characteristics, lifestyle, and environmental exposures. Digital biomarkers complement this approach by providing continuous and individualized health data that can be integrated with genomic, proteomic, and metabolomic information. Future pharmacovigilance systems are expected to combine genetic susceptibility markers, electronic health records, digital biomarker streams, medication exposure data, and environmental factors to develop highly personalized ADR prediction models. Such integration may improve medication safety by enabling individualized risk assessment and targeted preventive interventions.[40]

7.2 Expansion of Wearable and Implantable Technologies

Rapid advances in wearable sensor technologies are expected to improve the quality, accuracy, and diversity of digital biomarkers available for pharmacovigilance applications. Emerging technologies such as smart skin patches, flexible biosensors, implantable monitoring devices, smart textiles, and continuous biochemical monitoring systems may substantially expand the range of physiological and biochemical parameters that can be assessed in real time. These innovations have the potential to enhance early ADR detection and support more comprehensive patient monitoring outside traditional clinical settings [41].

7.3 Artificial Intelligence-Driven Pharmacovigilance Ecosystems

Future pharmacovigilance platforms are likely to incorporate advanced artificial intelligence systems capable of autonomous signal detection, risk

prediction, and clinical decision support. Such systems may automatically identify emerging drug safety signals, continuously learn from incoming patient data, generate dynamic risk prediction models, provide personalized medication safety recommendations, and facilitate automated regulatory reporting. These capabilities could significantly improve the efficiency and responsiveness of pharmacovigilance activities.[42]

7.4 Real-World Evidence Generation

Real-world evidence (RWE) is increasingly recognized as an important component of post-marketing drug safety evaluation. Digital biomarkers provide a valuable source of RWE because they capture patient experiences in everyday settings rather than controlled clinical environments [43].

7.5 Regulatory Evolution

Regulatory agencies worldwide are actively developing frameworks for evaluating digital health technologies and digital biomarkers. Future regulatory efforts are expected to focus on establishing standardized validation methodologies, ensuring interoperability across digital platforms, strengthening data privacy protections, improving transparency in artificial intelligence systems, and promoting international harmonization of digital health regulations. These developments will be essential for supporting the safe, reliable, and widespread adoption of digital biomarker-based pharmacovigilance systems.[44]

VIII. CONCLUSION

Adverse drug reactions remain a major challenge in healthcare despite significant advances in drug development and regulatory oversight. Traditional pharmacovigilance systems have contributed substantially to medication safety but are frequently constrained by underreporting, delayed signal detection, and limited real-time patient monitoring capabilities.

Digital biomarkers represent a transformative advancement in pharmacovigilance by enabling continuous, objective, and real-time assessment of physiological and behavioral changes associated with medication exposure. Data generated through wearable devices, smartphones, electronic health records, remote monitoring systems, and digital phenotyping platforms provide unprecedented opportunities for early ADR detection and prediction.

The integration of digital biomarkers with artificial intelligence and machine learning technologies has further enhanced the capability of pharmacovigilance systems to identify subtle safety signals, stratify patient risk, and facilitate personalized interventions. Applications in cardiology, psychiatry, oncology, endocrinology, and respiratory medicine demonstrate the broad utility of digital biomarker-driven approaches in improving medication safety.

Despite substantial promise, challenges remain regarding data quality, privacy protection, regulatory acceptance, algorithmic bias, and standardization. Addressing these limitations through collaborative efforts involving researchers, clinicians, technology developers, pharmaceutical industries, and regulatory agencies will be essential for successful implementation.

Overall, digital biomarkers are poised to redefine pharmacovigilance by shifting drug safety surveillance from a reactive model toward a proactive, predictive, and patient-centered paradigm. Continued technological innovation and regulatory advancement will likely establish digital biomarkers as a fundamental component of next-generation pharmacovigilance systems.

REFERENCES

[1] Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.

[2] Salas M, Gossell-Williams M, Yalamanchili P, Dhingra S, Malikova MA, Aimer O, et al. The use of biomarkers in pharmacovigilance: a systematic review of the literature. Biomark Insights. 2023; 18:1-15.

[3] Sameh A, Rostami M, Oussalah M, Korpelainen R, Farrahi V. Digital phenotypes and digital biomarkers for health and diseases: a systematic review of machine learning approaches utilizing passive non-invasive signals collected via wearable devices and smartphones. Artif Intell Rev. 2025; 58:66.

[4] Hu Q, Li J, Li X, Zou D, Xu T, He Z. Machine learning to predict adverse drug events based

on electronic health records: a systematic review and meta-analysis. J Int Med Res. 2024.
[5] Hu Q, Chen Y, Zou D, He Z, Xu T. Predicting adverse drug events using machine learning based on electronic health records: a systematic review and meta-analysis. Front Pharmacol. 2024; 15:1497397.
[6] Ward IR, Wang L, Lu J, Bennamoun M, Dwivedi G, Sanfilippo FM. Explainable artificial intelligence for pharmacovigilance: what features are important when predicting adverse outcomes? 2021.
[7] Coravos A, Khozin S, Mandl KD. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. NPJ Digit Med. 2019; 2:14.
[8] Babrak LM, Menetski J, Rebhan M, et al. Traditional and digital biomarkers: two worlds apart? Digit Biomark. 2019;3(2):92-102.
[9] Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: hype and hypothesis. Clin Pharmacol Ther. 2018;104(1):42-52.
[10] Dunn J, Runge R, Snyder M. Wearables and the medical revolution. Pers Med. 2018;15(5):429-448.
[11] Onnela JP, Rauch SL. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology. 2016; 41:1691-1696.
[12] Torous J, Kiang MV, Lorme J, Onnela JP. New tools for new research in psychiatry: a scalable and customizable platform to empower data-driven smartphone research. JMIR Ment Health. 2016;3(2): e16.
[13] Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13(6):395-405.
[14] Vegesna A, Tran M, Angelaccio M, Arcona S. Remote patient monitoring via non-invasive digital technologies. Telemed E Health. 2017;23(1):3-17.
[15] Insel TR. Digital phenotyping: technology for a new science of behavior. JAMA. 2017;318(13):1215-1216.
[16] Sarker A, Ginn R, Nikfarjam A, et al. Utilizing social media data for pharmacovigilance: a review. J Biomed Inform. 2015; 54:202-212.
[17] Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in wearable optical heart rate sensors. NPJ Digit Med. 2020; 3:18.
[18] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
[19] Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317-1318.
[20] Goldstein BA, Navar AM, Pencina MJ, Ioannidis JPA. Opportunities and challenges in developing risk prediction models with electronic health records data. J Am Med Inform Assoc. 2017;24(1):198-208.
[21] Harpaz R, DuMouchel W, Shah NH, et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010-1021.
[22] Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf. 2021;44(2):125-132.
[23] Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel P. Innovation in pharmacovigilance: use of artificial intelligence in adverse event case processing. Clin Pharmacol Ther. 2019;105(4):954-961.
[24] Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347-1358.
[25] Harpaz R, Vilar S, Dumouchel W, Salmasian H, Haerian K, Shah NH, et al. Combining signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013;20(3):413-419.
[26] Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24-29.
[27] Samek W, Wiegand T, Müller KR. Explainable artificial intelligence: understanding, visualizing and interpreting deep learning models. ITU J. 2017;1(1):39-48.
[28] Coravos A, Goldsack JC, Karlin DR, Nebeker C, Perakslis E, Zimmerman N, et al. Digital medicine: a primer on measurement. Digit Biomark. 2019;3(2):31-71.

[29] Steinhubl SR, Muse ED, Topol EJ. Can mobile health technologies transform health care? JAMA. 2015;313(5):459-460.

[30] Torous J, Wisniewski H, Bird B, Carpenter E, David G, Elejalde E, et al. Creating a digital health smartphone app and digital phenotyping platform for mental health and diverse healthcare needs. JMIR Ment Health. 2019;6(4): e11283.

[31] Weenk M, van Goor H, Frietman B, Engelen LJ, van Laarhoven CJ, Smit J, et al. Continuous monitoring of vital signs using wearable devices on hospital wards. J Med Internet Res. 2017;19(7): e249.

[32] Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 2005;28(5):1231-1239.

[33] Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment. J Clin Oncol. 2016;34(6):557-565.

[34] Eichler HG, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H, Raine J. From adaptive licensing to adaptive pathways. Clin Pharmacol Ther. 2015;97(3):234-246.

[35] Bent B, Cho PJ, Henriquez M, Wittmann A, Thacker C, Feinglos M, et al. Engineering digital biomarkers of interstitial glucose from noninvasive smartwatch data. NPJ Digit Med. 2021; 4:89.

[36] Price WN, Cohen IG. Privacy in the age of medical big data. Nat Med. 2019;25(1):37-43.

[37] Goldsack JC, Coravos A, Bakker JP, Bent B, Dowling AV, Fitzer-Attas C, et al. Verification, analytical validation, and clinical validation of digital health technologies. NPJ Digit Med. 2020; 3:55.

[38] Gianfrancesco MA, Tamang S, Yazdany J, Schmajuk G. Potential biases in machine learning algorithms using electronic health record data. JAMA Intern Med. 2018;178(11):1544-1547.

[39] U.S. Food and Drug Administration. Digital health technologies for remote data acquisition in clinical investigations: guidance for industry. Silver Spring (MD): FDA; 2023.

[40] Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507-522.

[41] Heikenfeld J, Jajack A, Rogers J, et al. Wearable sensors: modalities, challenges, and prospects. Lab Chip. 2018;18(2):217-248.

[42] Topol EJ. *Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again*. New York: Basic Books; 2019.

[43] Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence in medical product development. N Engl J Med. 2016;375(23):2293-2297.

[44] European Medicines Agency. *Regulatory Science Strategy to 2025*. Amsterdam: EMA; 2020.